Glaukos Reports Q4 Revenue, Maintains 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Jan 26
Source: NASDAQ.COM
Glaukos Corp (GKOS) shares rose 7.69% as the stock crossed above the 5-day SMA, reflecting positive investor sentiment amid broader market gains.
The company reported Q4 2025 revenue of $143 million, reaffirming its 2026 sales guidance of $600 million to $620 million, driven by the anticipated launches of Epioxa and iDose TR. Analysts maintain 'buy' ratings, indicating confidence in Glaukos' growth potential despite recent market pressures.
With a strong cash position of approximately $283 million and no debt, Glaukos is well-positioned for future investments, enhancing its competitive stance in the ophthalmic healthcare sector.
Analyst Views on GKOS
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
0 Hold
1 Sell
Strong Buy
Current: 119.070
Low
72.00
Averages
127.08
High
165.00
Current: 119.070
Low
72.00
Averages
127.08
High
165.00
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
